New immune targets identified in glioblastoma: CD44 and TNFSF14 may help guide future therapies

Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of only 15 months despite intensive treatment. Current therapies—including surgery, radiation, and chemotherapy—offer limited long-term benefit, and immune-based treatments have so far shown minimal success. The complexity of the tumor’s microenvironment and its ability to suppress immune responses contribute to the poor prognosis.

Accreditation process drives surgical quality improvement, study shows

About 800 U.S. hospitals have earned accreditation from the American College of Surgeons (ACS) between 2017 and 2023 through programs aimed at improving the quality of surgical care. Researchers found that while about 40% of hospitals fail to achieve accreditation on their first try, most that reapply ultimately meet the standards, according to a study published in the Journal of the American College of Surgeons.